Ramipril and Pancreatitis necrotising - a phase IV clinical study of FDA data
Summary:
Pancreatitis necrotising is found among people who take Ramipril, especially for people who are male, 50-59 old, have been taking the drug for 5 - 10 years.
The phase IV clinical study analyzes which people take Ramipril and have Pancreatitis necrotising. It is created by eHealthMe based on reports of 123,232 people who have side effects when taking Ramipril from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
123,232 people reported to have side effects when taking Ramipril.
Among them, 112 people (0.09%) have Pancreatitis necrotising.
What is Ramipril?
Ramipril has active ingredients of ramipril. It is often used in high blood pressure. eHealthMe is studying from 126,213 Ramipril users for its effectiveness, alternative drugs and more.
What is Pancreatitis necrotising?
Pancreatitis necrotising (inflammation of the pancreas cause death of tissue in pancreas) is found to be associated with 701 drugs and 339 conditions by eHealthMe.
Number of Ramipril and Pancreatitis necrotising reports submitted per year:

Time on Ramipril when people have Pancreatitis necrotising *:
Gender of people who have Pancreatitis necrotising when taking Ramipril*:
Age of people who have Pancreatitis necrotising when taking Ramipril *:
Common drugs people take besides Ramipril *:
Common side effects people have besides Pancreatitis necrotising *:
Common conditions people have *:
* Approximation only. Some reports may have incomplete information.
Do you take Ramipril and have Pancreatitis necrotising?
Check whether Pancreatitis necrotising is associated with a drug or a conditionHow to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
Related studies
How severe was Pancreatitis necrotising and when was it recovered:
Expand to all the drugs that have ingredients of ramipril:
Alternative drugs to, pros and cons of Ramipril:
- Ramipril (126,213 reports)
Common Ramipril side effects:
- Breathing difficulty: 8,189 reports
- Fatigue (feeling of tiredness): 7,681 reports
- High blood pressure: 6,751 reports
- Dizziness: 6,630 reports
- Diarrhea: 6,538 reports
- Hypotension (abnormally low blood pressure): 6,084 reports
- Weakness: 5,748 reports
Browse all side effects of Ramipril:
a b c d e f g h i j k l m n o p q r s t u v w x y zPancreatitis necrotising treatments and more:
- Pancreatitis necrotising (2,213 reports)
COVID vaccines that are related to Pancreatitis necrotising:
- Pancreatitis necrotising in Moderna COVID Vaccine
- Pancreatitis necrotising in Pfizer BioNTech Covid Vaccine
- Pancreatitis necrotising in Johnson and Johnson Covid Vaccine
Common drugs associated with Pancreatitis necrotising:
- Aspirin: 120 reports
- Byetta: 112 reports
- Ramipril: 112 reports
- Simvastatin: 110 reports
- Metformin: 104 reports
- Lisinopril: 101 reports
All the drugs that are associated with Pancreatitis necrotising:
- Pancreatitis necrotising (701 drugs)
Common conditions associated with Pancreatitis necrotising:
- High blood pressure: 203 reports
- Type 2 diabetes: 139 reports
All the conditions that are associated with Pancreatitis necrotising:
- Pancreatitis necrotising (339 conditions)
How the study uses the data?
The study uses data from the FDA. It is based on ramipril (the active ingredients of Ramipril) and Ramipril (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Systemic Lupus Erythematosus and drugs of ingredients of sulfamethoxazole; trimethoprim - now
- Xulane vs. Desogen - 2 seconds ago
- Benicar Hct vs. Microzide - 3 seconds ago
- Metoprolol Succinate vs. Capoten - 3 seconds ago
- Neoral and Simple Partial Seizures - 7 seconds ago
- Lymphoma and Metastases To Bone Marrow - 9 seconds ago
- Azor vs. Hydralazine Hydrochloride - 10 seconds ago
- Anzemet and Gastrointestinal Motility Disorder - 10 seconds ago
- Sulfapyridine vs. Azulfidine En-Tabs - 11 seconds ago
- Olmesartan Medoxomil and Psychomotor Hyperactivity - 14 seconds ago